Wednesday, November 12th, 2014

NORTHRIDGE, CA and CAMBRIDGE, UNITED KINGDOM -- (Marketwired) -- Avita Medical Ltd. (ASX: AVH) (OTCQX: AVMXY) a regenerative medicine company specializing in the treatment of wounds and skin defects, today announced that it has received an Australian R&D Tax Incentive payment of $1.4M for the financial year ending 30 June 2014.

"The payment resulting from Australia's R&D Tax Incentive program provides an important additional resource to innovate new advancements and explore additional applications for our proprietary technology platform, ReCell® Spray-On Skin®," commented Tim Rooney, Avita Medical's Interim Chief Executive Officer.


Avita Medical ( develops and distributes regenerative products for the treatment of a broad range of wounds, scars and skin defects. Avita's patented and proprietary tissue-culture, collection and application technology provides innovative treatment solutions derived from a patient's own skin. The Company's lead product, ReCell® Spray-On Skin®, is used in a wide variety of burns, plastic, reconstructive and cosmetic procedures. ReCell is patented, CE-marked for Europe, TGA-registered in Australia, and SFDA-cleared in China. ReCell is not available for sale in the United States; in the United States, ReCell is an investigational device limited by federal law to investigational use. A Phase III FDA trial is in process.


Avita Medical Ltd.
Tim Rooney
Interim Chief Executive Officer/Chief Financial Officer
Phone: + 1 (818) 827-1695 
Email: [email protected]

Avita Medical Ltd.
Lou Panaccio
Phone: +61 (0) 8 9474 7738
Email: [email protected] 


Avita, medical, medicine, wound, skin defect, scar, health



More Formats

View QR Code